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Abstract 
The synthesis and characterization of the four zinc(II) complexes [Zn(HL1)Cl2] (1), 
[Zn(H2L2)Cl2](2), [Zn(H2L3)Cl2] (3) and[Zn(H2L4)Cl2] (4), where HL1= (bis-2-pyridylmethyl)amine, 
H2L2= (2-hydroxybenzyl-2-pyridylmethyl)amine, H2L3= N-2[(pyridine-2-ylmethyl)amino)ethanol, 
H2L4= 1-[(pyridine-2-ylmethyl)-amino]-propan-2-ol are reported; (3) and (4) are new while (2) was 
reported previously but its structure had not been determined. The complexes were characterized by 
elemental analysis, IR, UV-Vis and NMR spectroscopies, electrospray ionization mass spectrometry 
(ESI(+)-MS) and tandem mass spectrometry ESI(+)-MS/MS). X-ray diffraction studies were performed 
for complexes (1)-(3) revealing the presence of mononuclear structures in the solid state. The x-ray 
analyses of (1) and (3) demonstrate that HL1 and HL2 act as tridentate ligands, while the ligand H2L2 in 
(2) is bidentate. The cytotoxic properties of the ligands and of all the complexes were examined using 
human leukemia THP-1, U937 and Molt-4 cells. Complex (4) exhibited the highest cytotoxicity in this 
series with an IC50 value of 75 ± 1 µmol L-1 against U937 cells. Transmission electron microscopy 
(TEM) reveals ultrastructural changes typical of apoptotic cells. The induction of apoptosis was 
confirmed by the annexin V assay. The antimicrobial activity of complexes (1)-(4) was also 
investigated in vitro against four Gram-positive bacteria (ATCC10832, ATCC25923, COL) and the 
clinical Staphylococcus aureus isolate LSA88 (SEC/SEF/TSST-1+). Complex (2) showed the most 
potent inhibitory activity, reaching almost 100% of inhibition against all strains tested. Morphological 
investigations using TEM indicate that the antibacterial activity of complex (2) may be associated with 
the inhibition of cell wall and therefore cell division. 
 
Keywords: Mononuclear Zn complexes; ESI(+)-MS/MS; Crystal structure; Antibacterial activity; 
Cytotoxic activity; Transmission electron microscopy (TEM). 
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1. Introduction 
 
Zinc has a vital importance in metabolism, being required for proper functioning of the immune 
system, the formation of red blood cells, organ, muscle and bone function, cell membrane stability, as 
well as cell growth, division, differentiation and genetics [1]. Zinc compounds are employed as 
radioprotective agents [2], tumor photosensitizers [3], antidiabetic insulin mimetics [4] and 
antimicrobial agents [5,6,7].  In 2012, Muthmary and co-workers reported the cytotoxicity of di-
zinc(II) complexes for human hepatoma HepG2 cancer cells, where these compounds were able to 
induce caspase-dependent apoptosis [8]. In 2013, Kessissoglou and co-workers reported the 
antimicrobial activity of zinc(II) complexes on five different microorganisms with IC50 values in the 
range of 1-4 µg.ml-1 [9]. Another established application for a zinc compound is as an anti-dandruff 
agent; zinc pyrithione (ZPT) is an antimicrobial compound used since 1960 in anti-dandruff shampoos 
and also anti-fouling paints [10]. In 2011, Saunders and co-workers reported that the ZPT efficacy 
against fungi is related to both the increasing concentrations of intracellular copper and the inactivation 
of Fe-S cluster-containing proteins [11]. 
Recently, we reported the antibacterial activity of iron(III), cobalt(II), copper(II) and zinc 
complexes, obtained with the ligand (N-(2-hydroxybenzyl)-N-(2-pyridylmethyl)[(3-chloro)(2-2-
hydroxy)]propylamine), against nine strains of S. aureus. Complexes containing cobalt and zinc 
showed the most potent inhibitory activity, reaching almost 100% of inhibition against the nine strains 
under investigation. Based on TEM studies, it was proposed that the zinc complex interacts directly 
with the genetic material of the S. aureus cells, promoting cell wall and cytoplasmic membrane 
damages, which result in the leakage of cellular content and inhibiting further division processes [12]. 
In that study, the metal ions were coordinated by tetradentate ligands which provide a pyridine, a 
phenol, an alcohol and a tertiary amine as coordinating groups. Due to the encouraging results obtained 
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with the zinc complex, we decided here to investigate simpler ligands, i.e. the tridentate bipodal ligands 
HL1= (bis-2-pyridylmethyl)amine, H2L2= (2-hydroxybenzyl-2-pyridylmethyl)amine, H2L3= N-
2[(pyridine-2-ylmethyl)amino)ethanol and H2L4= 1-[(pyridine-2-ylmethyl)-amino]-propan-2-ol). We 
also aimed to identify structural features related to the antibacterial activity of the corresponding zinc 
complexes. Furthermore, we also investigated the antitumor activity of these zinc complexes to probe a 
possible connection between these two biological activities.   It is worth noting that complex (1), the 
crystal structure of which is reported in this manuscript, was recently identified as an inhibitor of the 
activated RAS protein [13]. In cancer research RAS represents a target of high interest owing to its 
critical involvement in about 30% of all human malignancies [14]. 
 
2. Experimental  
2.1 Materials and methods 
 All the reagents and solvents were commercially available of high purity and used as such.  
The CHN elemental analysis for the complexes was performed on a Thermo Scientific FLASH 2000 
CHNS/O analyzer. Infrared spectra were recorded with KBr disks on a Shimadzu FT-IR 8300. Nuclear 
magnetic resonance (NMR) data were obtained using a JEOL eclipse 400+ spectrometer and deuterated  
dimethylsulfoxide (d6-DMSO) as solvent.  The electrical conductivity of a 1x10-3 mol.dm-3 solution of 
each complex was measured with a Biocristal conductometer, in MeCN. Melting points (MP) were 
measured on a Microquimica MQAPF-301 apparatus. Full scan mass spectra (MS mode) were obtained 
on a MicroTOF LC Bruker Daltonics spectrometer equipped with an electrospray source operating in 
positive ion mode. Samples were dissolved in a MeOH/H2O (1:1) solution and injected in the apparatus 
by direct infusion. To prepare the samples for transmission electron microscopy (TEM) the cells were 
cultured until reaching their final exponential and initial stationary phases. Pellets of cells were then 
harvested and processed for transmission electron microscopy (TEM) according to routine procedures 
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as follows: the control and cells treated with the coordination compounds were fixed in 2.5% 
glutaraldehyde, 4% paraformaldehyde diluited in 0.1 mol L-1 cacodilic buffer (pH = 7.2) and post-fixed 
in 1% osmium tetroxide and 0.8% potassium ferrocyanide, at room temperature, in the dark for 20 
minutes. After the fixing step, the dehydration process was conducted with 30, 50, 70, 80, 95 and 100% 
of acetone and samples were embedded in a crescent series of epoxy resin (Polybed 812®, EUA). Small 
blocks of the obtained polymer were cut with an ultramicrotome (Reichert Ultracut’s, Leica® 
Switzerland). Ultrathin sections were then negatively stained with uranyl acetate (5%) and lead citrate 
for observation in the microscopy (TEM 900 Zeiss, Germany), at 80 kV.   
 
2.2 Syntheses  
2.2.1 Synthesis of the ligands 
  The ligands employed in this work are presented in Scheme 1 and were synthesized as 
described  previously [15, 16, 17].  
 
2.2.2. Syntheses and characterizations of the complexes 
 The syntheses of the zinc complexes followed a similar synthetic route as exemplified below for 
the synthesis of the compound [Zn(HL1)Cl2] (1) (the syntheses and partial characterizations of 
complexes (1) and (2) were previously described in the literature [18,19]). Table 1 shows 
crystallographic data and Table 2 shows some data concerning the synthesis and characterization of the 
compounds (1)-(4). 
[Zn(HL1)Cl2] (1): An isopropanol solution (15 cm3) of ZnCl2.2H2O (136 mg, 1 mmol) was added to a 
methanol solution (15 cm3) of the ligand HL1 (200 mg, 1 mmol), resulting in a white solid.  The 
solution was heated (50-60ºC) until complete dissolution of the precipitate. The solution was 
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refrigerated for some days and white single crystals were formed, filtered off and washed with 
methanol.  
 
2.3 Crystal data collection and refinement 
The molecular structures of the complexes (1), (2) and (3) were solved by single crystal x-ray 
diffraction. Crystal data were collected at 295 K from an Enraf-Nonius Kappa-CCD diffractometer 
with graphite monochromatized Mo Kα radiation [20]. The cell parameters were obtained using the 
COLLECTA [21] and PHICHI [22] programs, and were refined using the DIRAX program [23]. 
Intensities were corrected by Lorentz polarization using the EvalCCD program [24], and absorption 
correction with the SADABS program [25]. The structures were solved as described in reference [26]. 
The positional parameters of the H atoms bonded to C atoms in the methylene moiety were obtained 
geometrically, with the C-H distances fixed at 0.96Å for Csp3 atoms, and their respective C atoms were 
refined with Uiso(H) = -1.2Ueq(Csp3). The positional parameters of the H atoms bonded to C atoms in 
the aromatic rings were obtained geometrically, with the C-H distances fixed at 0.93Å for Csp2 atoms, 
and set to ride on their respective C atoms, with Uiso(H) = 1.2Ueq(Csp2). The hydrogen atoms of the 
aminic and hydroxyl groups were located in Fourier maps and free refined to position.  
Crystallographic and structure refinement data for complexes (1)-(3) are shown in Table 1.  
 
 
Table 1. Crystallographic data and structure refinement for complexes (1), (2) and (3). 
 
 
Complexes (1) (2) (3) 
Empirical formula C12H13N3ZnCl2 C13H14N2OZnCl2 C8H12N2OZnCl2 
Formula weight  335.52 350.56 288.47 
T /K                     295(2) K 295(2) K 295(2) K 
Radiation, λ/Å  0.71073 Å 0.71073 Å 0.71073 Å 
Crystal System, space group Monoclinic, P21/n Triclinic,  P-1 Monoclinic, P21/c 
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Unit cell dimensions in (Å)  
and (°)       
a = 8.4981(17)  
b = 11.914(2)  
c = 14.405(3)  
β = 105.74(3) 
a = 8.3502(17)  
b = 9.4156(19)  
c = 11.005(2) 
α = 99.79(3) 
β = 111.48(3) 
γ = 108.24(3)  
a = 10.131(2) 
b = 8.0967(16)  
c = 14.367(3) 
β = 108.99(3) 
Volume /Å3 1403.8(5)  723.9(3) 1114.3(4 
Z 4 2 4 
Calculated density/g.cm-3 1.588  1.608 1.720 
Absorption coefficient /mm-1 2.114 2.057 2.652 
F(000)                                                                                       680 356 584 
Crystal size / mm3 0.17 x 0.12 x 0.10  0.76 x 0.47 x 0.27 0.22 x 0.21 x 0.15 
Theta range /°    3.05 to 25.49 2.10 to 25.50 3.29 to 25.00 
Reflections collected                                    29432 20491 19363 
Independent reflections 2614[R(int)=0.0726] 2667[R(int)=0.0520] 1954 [R(int) = 0.0406] 
Completeness to θ  max.                                          99.8 % 99.1 % 99.6 % 
Max. and min. transmission                                                     0.8148 and 0.7204 0.6066 and 0.3039 0.6981 and 0.5931 
Data / restraints / parameters                   2614 / 0 / 167 2667 / 0 / 181 1954 / 0 / 136 
Goodness-of-fit on F2 1.043 1.123 1.041 
Final Rindices [I>2sigma(I)] R1 = 0.0272 
wR2 = 0.0490 
R1 = 0.032  
wR2 = 0.0681 
R1 = 0.0199 
wR2 = 0.0425 
R indices (all data) R1 = 0.0478 
wR2 = 0.0531 
R1 = 0.0550  
wR2 = 0.0809 
R1 = 0.0258  
wR2 = 0.0440 
Extinction coefficient None 0.0174(18) 0.0009(3) 
Largest diff. peak and hole (e-
.Å-3)                                             
0.232 and -0.220 0.487 and -0.628 0.271 and -0.238 
 
2.4.Antileukemic activity studies 
2.4.1. Culture media 
Human leukemia cell lines THP-1 (acute monocytic), U937 (histiocytic lymphoma) and Molt-4 
(acute lymphoblastic) were cultured routinely in DMEM-F12 medium (Gibco, BRL),  supplemented 
with 10% fetal calf serum and gentamicin (20 µg/ml; Gibco, BRL) at 37 °C in a humidified atmosphere 
containing 5% CO2. Culture media were changed every 2–3 days. Blood samples were collected from 
healthy donors in Sodium Heparin glass tubes "VacutainerTM" (Becton Dikinson). Peripherical blood 
  
9 
 
mononuclear cells (PBMC) were isolated over Ficoll-Paque™ Plus (1.08 g/mL) in a 50 mL conical 
tube (2:1 - blood:ficoll). Twenty milliliters of a fresh, heparinized blood sample were diluted in 
phosphate-buffered saline (PBS), gently laid over 10 ml of Ficoll and centrifuged at 500xg for 20 min 
at 25 °C. PBMC rings were collected from the interface of blood samples and washed three times with 
PBS (phosphate buffered saline) by centrifugation at 500xg for 10 min at 4 °C. The supernatant was 
discarded and the cells were suspended in DMEM-F12 medium (Gibco, BRL). Trypan blue solution 
0.4% (Sigma, Germany) was used to count the cells into an appropriate concentration and the viability 
of cells was checked; the required range of cell viability was 95-99%.  
 
2.4.1. Screening for antileukemic activity 
In order to evaluate the in vitro antitumoral activity of complexes (1-4), their respective ligands 
and metallic salt were dissolved in DMSO and tested using THP-1, U937 and Molt-4 cells lines. 
Cisplatin and DMSO were used, respectively, as a positive and negative control of the assay. To 
determine cell viability the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) metabolic activity assay was used and IC50 values were calculated in order to evaluate the 
relationship between the structure and the activity of these synthetic compounds (IC50 is the 
concentration required for 50% of inhibition). The MTT assay assesses the capacity of the 
mitochondrial enzyme succinate dehydrogenase to transform the MTT salt into a purple colored 
product (formazan), which is proportional to the number of viable cells [27]. Leukemia cells (1 x 106 
cells mL-1) in DMEM-F12 medium supplemented with 10% fetal calf serum and 20 µg mL-1 
gentamicin were plated (100 µL/ well) in 96 well plates and treated with different concentrations of 
complexes (1-4) for 36 h and incubated at 37oC with 5% of CO2 and humidified atmosphere. Twenty 
microliters of MTT working solution (5 mg mL-1) were added into each well, and the cells were 
incubated at 37 °C for 4 h. Then, the MTT-formazan crystals produced by viable cells were dissolved in 
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an isopropanol-HCl solution.  The optical density (OD) values were measured by spectrophotometry at 
570 nm using a Microplate Reader (Multiskan-EX). The OD values are presented as relative viable cell 
numbers. For apoptosis analysis by Annexin V-FITC Apoptosis Detection kit (Sigma®) U-937 cells 
were seeded in 24-well plates at a density of 1 x 106 cells.mL-1 and treated with compound (4) at 
concentrations of 200 and 400 µmol L-1  and incubated at 37 ºC for 24 h in a humidified atmosphere 
with 5% CO2 .  After 24 h the cells were collected and washed in DPBS and suspended in binding 
buffer containing 5 µL of annexin V – FITC and 10 µL of propidium iodide.  The cells were incubated 
for exactly 10 minutes (protected from light) at room temperature, according to the manufacturer's 
recommendations. Data acquisition was performed by BD FACSCalibur with CELLQuest software and 
for data analysis, WinMDI software version 2.9 was used. For analysis of cell viability and apoptosis 
the mean and standard error were calculated from the raw data and then subjected to the One-way 
ANOVA- Turkey´s Multiple Comparison Test (for ZnCl2 and cisplatin) and two-way ANOVA- 
Bonferroni posttests (for all the complexes, ligands and metallic salt), software Graphpad version 5.0 
(analysis of variance). Significant difference was taken as *p < 0.05, ** p <0.01 and *** p <0.001. 
 
2.5. Antibacterial activity studies       
2.5.1. Microorganisms                  
Bacterial strains: S. aureus (ATCC10832, ATCC25923, COL) and the clinical S. aureus LSA88 isolate 
(SEC/SEF/TSST-1+) were obtained from the bacterial collection of the Laboratory of Animal Health 
(Laboratorio de Sanidade  Animal- LSA), Universidade Estadual do Norte Fluminense Darcy Ribeiro, 
RJ/ Brazil. 
 
2.5.2 Growth inhibition  
The inhibition assay was conducted by adding bacterial cells to grow in BHI (Brain Heart Infusion 
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Broth) medium during 24 h at 37 ºC. An aliquot of 0.1 mL of innoculum containing 108 cells/mL (0.5 
McFarland, Densimat (bioMérieux, France) was added to  1.85 mL of medium and  0.5 mL of each 
compound (ligands, coordination compounds and ZnCl2 at concentration of 10-2 mol L-1).  As positive 
and negative controls, gentamicin at concentration of 10-2 mol L-1 and DMSO were used, respectively. 
The growth curves were measured with a densitometer D.O.550nm (Densimat - bioMérieux, France) in 
intervals of 60 min. The assays were stopped when cell density reached 7.5 McFarland.  Each 
experiment was performed in triplicates and repeated twice. Inhibition percentages were thus reported 
as averaged values. 
2.5.3 Minimal Inhibitory Concentration (MIC)      
In vitro antibacterial activity of the complexes was investigated by the broth microdilution 
method according to the Clinical and Laboratory Standards Institute (CLSI 2009) document M7-A8 
[28]. Mueller Hinton broth (Acumedia, USA), supplemented with 2% glucose, was employed as the 
bacterial growth medium. Stock solutions of the compounds were prepared in DMSO and diluted in the 
same culture medium in serial, twofold concentrations in the range of 1.25x10-4–10-3 mol L-1. Through 
photometric readings (Densimat - bioMérrieux, France) the inoculum containing 1x108 CFU mL-1 
corresponding to 0.5 McFarland, were obtained from the broth cultures in the log phase of growth and 
diluted to 1x106 CFU mL-1. Subsequently, a 96 wells cell culture plate (TPP, USA) was used for MIC 
assays, and serial diluted chemical compound solutions (0.1 mL), inoculated in each sample of each 
bacterium strain (0.1mL), were incubated in a humid chamber at 37 ºC for 24 h. The MIC of each 
tested compound was defined as the lowest concentration exhibiting no visible growth compared to the 
drug-free control wells seen after the addition of 30 µL (1 mg/mL) of the dye resazurin (Sigma, USA). 
Gentamicin (Sigma, USA) was used as a reference antibacterial agent. A column of plate wells 
containing only inoculated medium was kept as the negative control. Metallic salt (ZnCl2) and ligand 
controls were also conducted simultaneously. All assays were performed in triplicates [28]. 
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3. Results and discussion 
In our attempt to generate compounds with effective biological activity (i.e. antitumoral and 
antibacterial), we focused on Zn(II) complexes with distinct N,O-donor  ligands, containing one or two 
aromatic chelating groups (Scheme 1).  We have selected those ligands since they allow us (i) to probe 
if different bipodal ligands have similar coordination behavior and (ii) to investigate the influence of 
the ligands' structure on the antibacterial and antitumor activities of these complexes.  
While the bipodal ligand HL1 induces a N3 coordination environment on the metal center, the 
bipodal ligands H2L2, H2L3 and H2L4 may generate a N2O coordination, where the O-donor center is 
provided by a phenol, a primary alcohol and a secondary alcohol, respectively. Ligands H2L3 and 
H2L4 are similar, but the ligand H2L4 presents a methyl group, which is absent in ligand H2L3.  
 The ligands and their respective zinc complexes are very stable in air. They are remarkably 
soluble in polar aprotic solvents such as DMF, DMSO and MeCN; slightly soluble in ethanol, methanol 
and chloroform; insoluble in water.  
The reactions between the ligands described and ZnCl2.2H2O allowed the isolation of crystals 
for all compounds. It was possible to determine the molecular structure through x-ray diffraction for 
compounds (1)-(3). Table 2 shows relevant data from the synthesis and characterization of the 
compounds (1)-(4).The conductivity behavior of complexes in MeCN was examined. The low 
conductivity values observed for complexes (1)-(4) suggest that they are non-electrolyte and indicate 
that the arrangement observed in solid state is the same in solution.  
The data presented in Table 2 indicate that the compounds are pure and that compounds (1)-(4) 
are neutral species. Scheme 1 presents the proposed structures of complexes (1)-(4), based on 
spectroscopic and structural data. 
 
Scheme 1 here 
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Table 2. Yield, melting point (M.P.), elemental analysis (C, H, N) and conductivity  data for complexes 
(1)-(4), in MeCN. 
Complex Composition M.W 
(g/mol) 
Yield 
(%) 
M. P. 
(oC) 
%C  
(Found/Calcd.) 
%H  
(Found/Calcd.) 
%N  
(Found/Calcd.) 
ΛM  
(cm2 Ω−1 mol-1) 
(1) Zn(HL1)Cl2 335.54 78 286 42.86/42.96 3.95/3.91 12.56/12.52 5.6 
(2) Zn(H2L2)Cl2 350.55 79 193 44.57/44.54 4.03/4.03 8.24/7.99 17.3 
(3) Zn(H2L3)Cl2 288.48 63 169 33.47/33.31 4.21/4.19 9.98/9.71 3.8 
(4) Zn(H2L4)Cl2 302.51 68 175 35.40/35.73 4.89/4.66 9.16/9.26 16.8 
 
3.1. IR and NMR spectra 
The IR spectra of complexes (1)-(4) were analyzed in comparison with those of their common 
free ligands HL1-H2L4 in the region 4000-400 cm-1. The IR spectra of free ligands are similar and show 
characteristic absorption bands: νN-H ,νC=C, νC=N and δ(pyridine ring). For ligand HL1, characteristic bands 
of the pyridine group are observed at 1593, 1435 and 758 cm-1, assigned to νC=N, νC=C and δ(pyridine ring), 
respectively. The νN-H  band is observed at 3344 cm-1 for ligand HL1. For ligand H2L2, characteristic 
bands of the pyridine group are observed at 1593, 1430 and 756 cm-1, assigned to νC=N, νC=C and 
δ(pyridine ring), respectively. The νN-H  band is observed at 3263 cm-1. There is a band at 1280 cm-1, 
attributed to the phenol group (νC-O). For ligand HL3, characteristic bands of the pyridine group are 
observed at 1595, 1435 and 762 cm-1, assigned to νC=N, νC=C and δ(pyridine ring), respectively. The νN-H  
band is observed at 3300 cm-1. For ligand H2L4, characteristic bands of the pyridine group are 
observed at 1595, 1437 and 764 cm-1, assigned to νC=N, νC=C and δ(pyridine ring), respectively. The νN-H  
band is observed at 3300 cm-1. For all the complexes, the bands due to νN-H and δ(pyridine ring) exhibited 
downward and upward shifts, respectively, after coordination to ZnCl2. For complexes (1)-(4), the νN-H 
are observed at 3244, 3226, 3228 and 3178 cm-1, and δ(pyridine ring)  are observed at 760, 760,779 and 767 
cm-1, respectively. The bands attributed to νC=N exhibited a downward shift, resulting in bands at 1570, 
1570 and 1573 cm-1, respectively for complexes (1), (3) and (4). For complex (2), no shift was 
observed for the band νC=N; furthermore, the presence of a band at 1273 cm-1 indicates the presence of 
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the phenol group in the structure of the complex, in good agreement with the crystal data. Table 3 
presents the characteristic bands of L1-L4 and their respective complexes. 
Table 3. The characteristic IR bands of the ligands L1-L4 and their respective complexes, in cm-1. 
 HL1 (1) H2L2 (2) H2L3 (3) H2L4 (4) 
νN-H 3344 3244 3263 3226 3300 3228 3300 3178 
νC=N, 1593 1570 1593 1593 1595 1570 1595 1573 
νC=C 1435 1442 1430 1435 1435 1446 1437 1442 
δ(pyridine 
ring) 
758 760 756 760 762 779 764 767 
phenol 
(νC-O) 
---  1280  ----  --- 1273 
The 1H NMR spectra for the complexes are presented in Figure 1. To facilitate the 
interpretation, the carbon atoms in the ligands are numbered, and the numbers on the signals indicate 
the hydrogen atom attached to these carbon atoms. The spectra for complexes (1), (3) and (4) show a 
similar profile related to the aromatic region (7.0-9.0 ppm), which is attributed to the hydrogen atoms 
of the pyridine group. Interestingly, while these complexes show only three signals related to these 
aromatic hydrogen atoms, their free ligands display four signals (see Table 4). The integral ratio and the 
coupling constant indicate that the signals of the hydrogen atoms bound to the carbon atoms 2 and 4 
were merged in a multiplet around 7.56 ppm.  
 For complex (1) the methylenic hydrogen (CH2) from the ligand HL1 is observed at 4.13 ppm 
with a very broad shape, while in the free ligand it appears as a narrow singlet at 3.90 ppm. For the 
same complex, the amine hydrogen atom was observed at 2.90 ppm in the free ligand and appears at 
4.93 ppm in the complex. This shift is in agreement with the fact that the electron density on the 
nitrogen atom is lower in the complex than in the free ligand. 
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 The spectrum of complex (3) shows the methylenic group attached to the aromatic ring as a 
singlet at 4.06 ppm (3.92 ppm in the free ligand).  There are also two triplets (J = 5.5 Hz) associated 
with the other two methylenic groups, at 3.51 and 2.78 ppm. The former is the one bound to the alcohol 
group while the latter is connected to the amine nitrogen atom.  
For complex (4), the hydrogen atoms from the py-CH2-N unit were split in two doublets with J 
values of 15.6 Hz, typical of geminal hydrogen atoms.  The hydrogen atom bound to C8 appears at 3.74 
ppm as a broad singlet, while the hydrogen atoms from the methylenic and methyl groups are observed 
at 2.77 ppm (dd, J1 = 11.8 Hz; J2= 3.13 Hz) and 1.07 ppm (d, J = 6.3 Hz), respectively. 
 The spectrum of complex (2) differs significantly from the others, since it possesses two 
different aromatic rings (pyridine and phenol), resulting in a larger number of signals in the 1H NMR 
spectrum between 6 and 9 ppm. The assignment of the hydrogen atoms from the pyridinic group may 
be established by comparison to the compounds described above. However, it should be pointed out 
that some of the aromatic hydrogen atoms are presenting two different signals, accounting to a ratio of 
20-30/70-80 %. For example, the hydrogen atom attached to C1 presents just one signal in compounds 
(1), (3) and (4). However, in (2) there are two signals associated with this hydrogen atom (8.75 ppm, d, 
J = 4.0 Hz and 8.59 ppm, d, J = 3.1 Hz). Similarly, there are other signals in the aromatic range which 
present the same ratio and are associated with the same hydrogen atoms (C3-H, C4-H, C11-H). On the 
other hand, there are some signals that are not split (C2-H, C9-H, C10-H, C12-H). We have already 
observed the same behavior with another zinc compound synthesized with a ligand which also contains 
pyridine and phenol groups; those studies seem to indicate the presence of different isomers in solution 
[9]. The aliphatic region is dominated by two intense broad signals at 3.95 ppm and 4.08 ppm, which 
are associated with the methylenic hydrogen atoms. There are also some side peaks that again suggest 
the presence of different isomers in solution. In the free ligand the methylenic hydrogen atoms appear 
at 4.00 and 3.83 ppm. Table 4 shows the relevant 1H NMR spectral data with assignments. 
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Table 4. 1H NMR spectral data with assignments for ligands HL1-H2L4 and their respective 
complexes. 
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H L1 ZnL1 (1) L2 ZnL2 (2) L3 ZnL3 (3) L4 ZnL4 (4) 
 δ/M/J (Hz) δ/M/J (Hz) δ/M/J (Hz) δ/M/J (Hz) δ/M/J (Hz) δ/M/J (Hz) δ/M/J (Hz) δ/M/J (Hz) 
1 8.48/dd/ 4.0; 1.8 8.78/d/4.7 8.58/dd/5.3; 1.7 8.76/d/4.0 
8.59/d/3.1 
8.47/d/4.2 8.56/d/5.08 
 
8.54/d/4.2 8.55/d/4.7 
 
2 7.07/m 7.55/m 7.19/m 7.50/m 7.11/dd/7.7; 
4.4 
7.55/m 
 
7.15/dd/7.7; 4.8 7.53/m 
 
3 7.56/dt/7.7; 1.8 8.02/dt/7.6; 1.6 7.65/dt/7.7; 1.7 7.96/t/7.6 
7.70/dt/7.8; 1.6 
7.59/dt/7.7; 1.5 8.03/dt/8.0; 1.5 
 
7.63/dt/7.7; 1.8 8.01/dt/7.8; 1.2 
 
4 7.28/d/7.7 7.55/m 7.19/m 7.50/m 
7.08/d/7.4 
7.23/d/7.7 7.55/m 
 
7,26/d/7.7 7.53/m 
 
6 3.90/s 4.13/s 3.83/s 3.95/s 3.87/s 4.06/s 3.91/s 4.06/d/15.6 
3.98/d/15.6 
7 - - 4.0/s 4.08/s - - - - 
9 - - 6.97/d/7.3 7.25/d/6.6 - - - - 
10 - - 6.77/dt/7.3; 0.9 6.78/t/7.4 - - - - 
11 - - 7.19/m 6.36/t/7.0 
7.17/t/7.6 
- - - - 
12 - - 6.86/m 6.86/d//6,9 
6,89/d/6,9 
- - - - 
13 - - - - 2.76/t/5.3 2.78/t/5.5 
 
2.74/dd/12.9; 2.2 
2.41/dd/12.9; 9.5 
2.76/dd/12.0; 3.1 
 
14 - - - - 3.61/t/5.3 3.51/t/5.5 
 
3.81/m 3.73/ m 
 
15 - - - - - - 1.13/d/6.2 1.06/d/6.2 
 
δ= chemical shift; M = signal multiplicity, J =  coupling constant.
  
18 
 
3.2. Structure of the complexes 
3.2.1. Description of the structure of complexes (1)-(3) 
 The single crystal x-ray studies are in agreement with the above spectroscopic 
analysis and show three new structures of mononuclear zinc complexes with σ-
N3(HL1), σ-N2(H2L2) andσ-N2O1 (H2L3) donor sets. The ORTEP-3 projection of (1), 
(2) and (3) are shown in Figures 2-4, respectively.  Bond lengths and bond angles are 
listed in Table 5. These parameters are in agreement with literature values [29] and 
within the expected range for compounds of this class, as presented by the International 
Tables for X-ray Crystallography [30].  
 
Table 5. Selected bond lengths [Å] and angles [°] for complexes (1), (2) and (3). 
 
Bond lengths (1) (2) (3) 
Zn1-N1 2.1548(19) 2.031(2) 2.1244(16) 
Zn1-N2 2.146(2) 2.057(3) 2.0971(17) 
Zn1-N3 2.158(2) ----- ----- 
Zn1-O1 ----- ----- 2.3150(17) 
Zn-Cl1 2.2650(7) 2.1988(10) 2.2180(7) 
Zn-Cl2 2.2598(7) 2.2214(13) 2.2679(7) 
N2-C6   1.453(3) 1.475(4) 1.463(2) 
N2-C7 1.461(3) 1.475(4) 1.463(3) 
N1-C5 1.332(3) 1.343(4) 1.334(2) 
N1-C1 1.335(3) 1.315(4) 1.327(3) 
O1-C8 ----- ----- 1.410(3) 
O1-C9 ----- 1.337(4) ----- 
Bond angles (1) (2) (3) 
C6-N2-C7 115.7(2) 113.7(2) 114.22(16) 
N2-Zn1-N1 76.00(7) 81.66(10) 77.95(6) 
N2-Zn1-N3 76.44(8) ----- ----- 
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N1-Zn1-N3 150.22(8) ----- ----- 
N2-Zn1-Cl2 139.63(6) 113.74(9) 124.64(5) 
N1-Zn1-Cl2 96.53(5) 109.13(8) 98.30(5) 
N3-Zn1-Cl2 97.16(6) ----- ----- 
N2-Zn1-Cl1 103.56(6) 112.38(8) 115.11(5) 
N1-Zn1-Cl1 97.76(6) 116.17(8) 103.69(5) 
N3-Zn1-Cl1 99.43(6) ----- ----- 
Cl2-Zn1-Cl1 116.80(4) 118.25(4) 119.26(2) 
N2-Zn1-O1 ----- ----- 74.00(6) 
N1-Zn1-O1 ----- ----- 151.08(6) 
Cl1-Zn1-O1 ----- ----- 94.51(5) 
Cl2-Zn1-O1 ----- ----- 91.94(5) 
 
Incomplete structural data for complex (1) were previously reported in 1992 
[31]. In 2007, Kang and co-workers reported the structural data for the complex 
[ZnCl2(HL1)].CHCl3, revealing the presence of a chloroform as solvate in the molecular 
structure [32]. Here, we are reporting the structural data for complex (1) without solvate 
molecule (Figure 2).  In (1), the zinc center is coordinated by a σ-N3 donor set provided 
by the ligand HL1, via  one aminic nitrogen atom (N2H), two pyridinic nitrogen atoms 
(N1 and N3) and two chloride anions (Cl1 and Cl2), resulting in a pentacoordinated 
zinc(II) complex with a N3Cl2 coordination environment around the zinc(II) center. The 
tridentate ligand HL1 is linked to the zinc(II) ion by two five-membered rings, with the 
following bite angles: 76.00(7°) from N1-Zn-N3 and 76.44(8°) from N2-Zn-N3. In this 
complex the τ parameter  (τ = (β−α)/60 = 0.18) indicates a slightly distorted square 
pyramidal geometry [33]. The basal positions are occupied by N1, N2, N3 and Cl2, 
while the axial position is occupied by Cl1 atom. The base of the pyramid shows the 
following angles: β = 150.22(8)° from N1-Zn1-N3 and α = 139.63(6)° from N2-Zn1-
Cl2. The zinc center shows a dihedral angle with N1/C5/C6/N2 plane of 30.4(1)° and a 
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torsion angle for this fragment (N1-C5-C6-N2) of -24.2(3)°.  The zinc atom shows a 
deviation of 0.594 Å out of the N1/N2/N3/Cl2 plane.  
 Although it has been shown that the ligand H2L2 usually provides a N2O1 
donor set, when reacted with to ZnCl2.2H2O [34, 16, 35], it acts as a bidentate ligand 
through the aminic (N2) and the pyridinic nitrogen (N1) atoms (Figure 3). The distorted 
tetrahedral geometry presented by the zinc center is completed by two chloro ligands. 
The angles around the zinc center are 81.7(1)° for N1-Zn1-N2 and 118.26(4)° for Cl1-
Zn1-Cl2. The phenol group remains protonated after coordination  and away from the 
metal center, indicating that the hydrogen bonds of the O1H from the phenolate group 
with H6B (from C6) and H7B (from C7) are strong. This behavior is different from 
what we observed previously in the compound [ZnII(HBPClNOL)Cl], in which the 
phenol group is coordinated to the zinc center as an anion [12]. This suggests that the 
Zn(II) ion in (2) has a lower acidity than in the complex [ZnII(HBPClNOL)Cl]. The 
structure for complex (2) is in excellent agreement with that proposed by Tandon and 
co-workers in 1994 [19].The molecular structure of the complex (3) reveals a 
pentacoordinated zinc center (Figure 4), which adopts a strongly distorted square 
pyramidal geometry (τ = 0.44). The basal positions are occupied by N1, N2, O1 and Cl2 
atoms, and the axial position is occupied by the Cl1 anion.  The basal angles are β = 
151.08° for N1-Zn1-O1 and α = 124.64° for N2-Zn1-Cl2. Although the ligand H2L3 is 
very similar to H2L2, also providing a N2O donor set, it is able to act as a tridentate 
ligand, while the latter showed a bidentate coordination behavior. Thus, the Zn(II) ion 
coordinates to the H2L3 ligand via the  pyridinic nitrogen atom (N2), aminic nitrogen 
atom (N1) and by the  alcohol group (O1H). Two chloride anions (Cl1 and Cl2) are also 
bound to the Zn(II) center, resulting in a N2OCl2 coordination environment.  The two 
five-membered rings observed in the complex have bite angles of 77.95(6)° in N2-Zn1-
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N1 and 74.00(6)° for N2-Zn1-O1, which are very similar to those observed in complex 
(1).  The zinc atom shows a deviation of 0.715 Å out of the N1/N2/O1/Cl2 equatorial 
plane. The metal atom forms a dihedral angle with the N1/C5/C6/N2 plane of 27.2(1)° 
and an N1-C5-C6-N2 torsion angle of -31.6(2)°. The dihedral angle formed by 
N2/C7/C8/O1 is 17.1(1)° and the torsion angle in this N2-C7-C8-O1 moiety is 
52.43(2)°. 
 
3.3. ESI(+)-MS and ESI(+)-MS/MS studies 
 For complex (1), in a water/methanol solution (1:1), signals associated with 
mononuclear and dinuclear species are observed ([Zn(NaL1)Cl]+ (m/z 322) and 
[(HL1)(OH2)(OH)Zn-(µ-Cl)-Zn(HL1)(OH)(H2O)]+ (m/z 635)), as well as signals related 
to the free ligand [H2L1]+ (m/z 200). The observation of the m/z 635 species in the 
MS/MS spectrum suggests the formation of the mononuclear cation 
[Zn(HL1)(OH)(OH2)]+ (m/z 300), by the loss of the neutral molecule 
[Zn(HL1)(Cl)(OH)(OH2)] (m/z 335).  
As complex (2) is neutral, i.e. [Zn(HL2)Cl2], no signal associated with this 
species is observed. However, in a water/methanol (1:1) solution, twelve additional 
signals and their characteristic set of iso-topolog ions, due mainly to the presence of Zn 
and Cl atoms, are clearly detectable (data not shown). These signals are related to 
mono- and dinuclear species containing Zn, e.g: [Zn(HL2)]+ (m/z 277), [Zn(H2L2)Cl]+ 
(m/z 313), [Zn(NaHL2)Cl]+ (m/z 335), [Zn(NaH2L2)(OH)(Cl)(CH3OH)]+ (m/z 385), 
[Zn(H2L2)(HL2)]+ (m/z 493), [Zn(H2L2)(HL2)(CH3OH)2]+ (m/z 555), [(HL2)Zn-(µ-
OH)-Zn(HL2)]+ (m/z 571), [(HL2)Zn-(µ-Cl)-Zn(HL2)]+ (m/z 589) and [(NaHL2)Zn-(µ-
Cl)-Zn(HL2)Cl]+ (m/z 647). In addition, a signal attributable to the ligand H2L2 (i.e. 
[H3L2]+ (m/z 215)) is observed.  MS/MS studies indicate that the ion of m/z 533 may 
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yield the cation [Zn(H2L2)(HL2)]+ (m/z 493) by the loss of solvent, suggesting that the 
m/z 533 species is probably a solvent cluster of the [Zn(H2L2)(HL2)]+ (m/z 493) ion.  
MS/MS analysis of the species with m/z 493 yields the cation [Zn(HL2)]+ (m/z 279) and 
the neutral molecule of the ligand H2L2 (m/z 214). The ion corresponding to m/z 482 
may be associated with dimerization of the H2L2 ligand and solvent molecules. MS/MS 
data of the ion with m/z 482 indicates the formation of C7H6O (m/z 106), as reported 
previously [24].  In water/methanol solutions interesting association processes are 
observed rendering the species [(HL2)Zn-(µ-OH)-Zn(HL2)]+ (m/z 571), [(HL2)Zn-(µ-
Cl)-Zn(HL2)]+ (m/z 589) and [(NaHL2)Zn-(µ-Cl)-Zn(HL2)]+ (m/z 647) as a result of the 
interaction between the two [Zn(HL2)]+ m/z 277 ions. The ion with m/z 571 is formed 
by the interaction between two species of m/z 277 via a hydroxo bridge; the ion with 
m/z 589 is formed by an interaction between two species with m/z 277 involving a 
chloride bridge and for the ion with m/z 647it is suggested that it may contain the 
species with m/z 589 plus a chloride and a sodium ion. ESI(+)-MS/MS of these ions  
were unsuccessful due the low intensity of the majority of the signals. ESI(+)-MS/MS 
for the species with m/z 277, 482 and 491 are also structurally characteristic, indicating 
only the presence of the ligand H2L2 in these fragments. 
 ESI(+)-MS data for complex (3) indicate the presence of five cations in 
water/methanol (1:1) solution: [H3L3]+ (m/z 153), [Zn(HL3)]+ (m/z 215), 
[Zn(H2L3)2(Cl)]+ (m/z 403), [(HL3)Zn-(µ-Cl)-Zn(H2L3)Cl]+ (m/z 505) and 
[(H2L3)(Cl)Zn- (µ-Cl)-Zn(H2L3)(Cl)]+ (m/z 541). The ESI(+)-MS/MS of the ion with 
m/z 541 is also structurally characteristic; the ion loses an HCl molecule to form a 
fragment ion with m/z 505 [Zn2(HL3)(H2L3)Cl2]+. The loss of two HCl molecules leads 
to the formation of the fragment ion with m/z 469, [Zn2(HL3)2Cl]+. The loss of the 
neutral complex [Zn(H2L3)Cl2] (m/z 288) results in a fragment ion with m/z 253 
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[Zn(H2L3)Cl]+. 
 For complex (4) five species were detected in the ESI(+)-MS spectrum: 
[NaH2L4]+ (m/z 189), [NaZn(HL4)Cl)]+ (m/z 287), [Zn(H2L4)(HL4)]+ (m/z 395), 
[NaZn2(L4)2]+ (m/z 480) and [Zn2(HL4)2Cl]+  (m/z 495). The ESI(+)-MS/MS data for 
these species indicate  the presence of the ligand H2L4. Figure 5 illustrates some 
species detected in the ESI(+)-MS and ESI(+)-MS/MS spectra for compounds (2) and 
(4) in H2O/MeOH. Based on the ESI(+)-MS and ESI(+)-MS/MS data, it is suggested 
that complex (4) is mononuclear in the solid state, with the zinc center coordinating to 
one molecule of the H2L4 ligand and to chloride ions, thus resulting in a neutral 
complex, in good agreement with other results (i.e. conductivity measurements, NMR 
and elemental analysis, see above). In solution it can however dimerize, as observed for 
the other compounds.  
The spectra and the proposed structures based on the isotopic pattern for the 
main ion of each complex are supplied in the Supplementary material. 
 
3.4. Antileukemic activity of the complexes 
In order to study the antitumoral activity of the zinc complexes (1)-(4), their 
cytotoxicity against THP-1, U937 and Molt-4 human leukemia cell lines was 
investigated (Table 6). Complex (4) has a lower IC50 value (75 ± 1 µmol L-1) for the 
U937 cell line, and is the complex with the highest activity of this series. Ligand HL1 is 
the only ligand with measurable antitumoral activity in the three cell lines under 
investigation, with an IC50 value of 52 ± 1 µmol L-1 in the Molt-4 cell line. No 
potentiating effect is observed upon coordination of HL1 to ZnCl2 since complex (1) 
exhibits very low activity against U937 and Molt-4 and moderate activity against THP-1 
cell lines (116 ± 1 µmol L-1). Based on their IC50 values, the zinc complexes are only 
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weakly active, at best over an order of magnitude less potent than cisplatin. 
Table 6. The 50% inhibitory concentration (IC50) of the zinc complexes described in this 
study and their respective ligands, as well as DMSO and cisplatin, for leukemia cancer 
cell lines (THP-1, U937 and Molt-4).  
Compound IC50 (µmol L-1) 
THP-1 U937 Molt-4 
HL1 118.5 ± 10.5 141 ± 1 55 ± 3 
(1) 103.5 ± 12.5 > 400 > 400 
H2L2 > 400 > 400 > 400 
(2) 107  ± 19 > 400 > 400 
H2L3 > 400 > 400 > 400 
(3) 108.5 ± 6.5 122 ±1 210 ± 8 
H2L4 > 400 > 400 > 400 
(4) 98.5 ± 8.5 75 ± 1 235.5 ± 5.5 
Cisplatin 9.5 ± 1.5 7.5 ± 0.5 6 ± 1 
ZnCl2 302 ± 8 123± 13 137 ± 1 
The cytotoxicity of the complexes was determined after 36 h of incubation, using the 
MTT method [27]. * Data represent the mean of a triplicate experiment which was 
repeated twice. 
 
Based on the moderate activity of complex (4) in the U937 cell line, we decided 
to investigate the mechanism of cell death promoted by this complex. For this purpose, 
the Annexin V-FITC/PI staining assay was employed. In this assay, U937 cells stained 
single-positive for Annexin V-FITC are considered mostly early apoptotic cells and cells 
stained single-positive for PI are predominantly necrotic cells.  Cells that are stained 
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double-positive are considered as late apoptotic or secondary necrotic cells [36]. The 
Annexin V-FITC/PI staining data indicate that the percentage of apoptosis was 90.8% 
and 99.1%, respectively, after treatment for 24h with 200 and 400 µmol L-1 (4), 
respectively (see Figure 6c and 6d). For comparison, Figure 6a presents the results for a 
control group and Figure 6b those collected in presence of cisplatin.  For cisplatin, the 
apoptosis and necrosis rates are 41 % and 16 %, respectively, while the normal cells 
reaches 44%, at a concentration of 50 µmol L-1 after 24h of incubation. These data 
strongly suggest that complex (4) could effectively induce apoptosis in U937 cells in a 
concentration-dependent manner. It is worth noting that apoptosis is a desired pathway 
for cell death to occur when developing anticancer agents since apoptosis or 
programmed cell death is central to the development of homeostasis of metazoans [37]. 
 
3.5. Transmission Electron Microscopy 
3.5. 1.Morphological changes of the leukemia cell line U937 after treatment with 
complex (4)  
 In order to directly observe the morphological changes of the internal structure 
of human leukemia cells (THP-1 and U937) after the treatment with complex (4), 
transmission electron microscopy (TEM) was employed. 
 After incubation times, which varied from 6 h to 12 h, samples were collected to 
measure cell density and morphological changes.  The concentration of complex (4) was 
also varied (100 and 200 µmol L-1, respectively) to assess its effect on the cells. 
 Figure 7 shows the morphological changes promoted by complex (4), at a 
concentration of 100 µmol.L-1 after 6 h of incubation. A clear association between 
mitochondria (M) and endoplasmic reticulum (ER) was observed, indicating the 
initiation of apoptosis.  At a concentration of 200 µmol. L-1 and after 12 h of incubation 
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(Figure 8), an intense vacuolization of the cells, condensation of the nuclear chromatin 
(NC) and the formation of vacuoles (V) were clearly observed. Figure 8 also 
demonstrates the intense association between mitochondria (M) and the endoplasmic 
reticulum (ER), as well as the formation of membrane blebs (B). Blebs are typical of 
apoptotic cells, indicating that complex (4) is promoting cell death via an apoptotic 
mechanism. 
 
3.5.2. Morphological changes of the leukemia cell line THP-1 after treatment 
with complex (4)  
THP-1 cells were treated similarly (6-12 h incubations at complex 
concentrations of 100 and 200 µmol L-1). An increased association between 
mitochondria (M) and the endoplasmic reticulum (ER) was also observed, as well as a 
large number of structurally altered mitochondria and large vacuoles with membranous 
structures, shown in Figures 9 and 10, respectively.  In Figure 9, ER-like elements in 
close proximity to highly altered mitochondria (M) appear with an empty matrix (star), 
displaying only cristae structures, or possibly extruding their content, resulting in the 
formation of a vacuole (arrow). Different stages of cell death are observed, leading 
ultimately to the appearance of abnormal mitochondria (M) and their subsequent 
destruction, as well as the formation of vacuoles with membranous content (V). Figure 
10 shows a multitude of long vacuoles (V) with membranous structures inside (star).  
 
3.6. Antibacterial activity of the complexes 
 Since we have previously described that the zinc complex [Zn(HBPClNOL)Cl] 
was very effective on different S. aureus strains, we were interested in evaluating if 
simpler zinc complexes would show similar activity.  Table 7 presents the 
NC 
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antibacterial activities of the complexes (1)-(4), of the metallic salt, and of their 
respective ligands and gentamicin (standard drug), which were evaluated in terms of 
growth inhibition curves (i.e. percentage of inhibition) of S. aureus strains 
(ATCC10832, ATCC25923, COL and LSA88).  
Complex (2), at a concentration of 10-2 mol L-1, showed the best inhibitory 
activity reaching  100% of inhibition on each of the four strains under investigation. In 
contrast, complex (4) was the least effective, showing very low inhibitory activity 
against ATCC25923 (0%), COL (17%) and LSA88 (16%). However, this complex 
showed high antibacterial activity against ATCC10832 (96%), demonstrating the effect 
of the coordination of zinc to the ligand, since no activity was observed for the ligand 
H2L4 alone (see Table 7). The values for the percentage of inhibition of complex (4) are 
very similar to those of its respective ligand H2L4: ATCC25923 (0%), COL (12%) and 
LSA88 (5%). Ligands H2L3, H2L3 and H2L4 showed low inhibitory activities against 
this group of tested bacteria (ATCC10832 (5, 0 and 0%, respectively), ATCC25923 (2.4, 
0 and 0 %, respectively), COL (11, 12 and 12%, respectively) and LSA88 (6.2, 4 and 
5%, respectively)), thus demonstrating that the antibacterial activity of zinc complexes 
against ATCC10832 is the result of a potentiating effect between the ligands H2L2, 
H2L3 and H2L4 and zinc(II) ion. For complex (1), high activity was observed only 
against ATCC10832 (96%). Since complex (2) was the most active, experiments to 
determine its minimum inhibitory concentration (MIC) were carried out against the 
same strains of S. aureus, resulting in values of 512 µg/mL, 512 µg/mL, 512 µg/mL and 
> 512 µg/mL to ATCC 10832, ATCC 25923, COL and LSA88, respectively (512 µg/mL 
≈ 1.46 mmol L-1). 
The values obtained for ATCC10832 and ATCC25923 are 32 times higher than 
those determined with gentamicin, a clinical drug. However, for COL, the MIC was 
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only twice the value determined for gentamicin. Previously reported MIC values for the 
complex [Zn(HBPClNOL)Cl], the most active against nine strains of S. aureus, are 
cited, which were all shown to be ~100 times higher than those obtained with 
chloroamphenicol [12]. As presented in Table 7, complex (2) was the most active and its 
antibacterial activity could be related to the phenol group and to the potentiating effect 
between the ligand H2L2 and ZnCl2. The same effects were observed for complex 
[Zn(HBPClNOL)Cl], reported previously [12]. This complex presents a phenol group 
coordinated to the zinc(II) center and showed the best inhibitory activity, reaching 
almost 100% of inhibition against nine strains of S. aureus under investigation. 
Table 7. Antibacterial activities of the complexes (1)-(4), their respective ligands, 
metallic salt and gentamicin against pathogenic bacteria (S. aureus) after 10 h of 
incubation. 
Compound % inhibition promoted by the compounds 
S. aureus 
ATCC10832 ATCC25923 COL LSA88 
HL1   8  7  15.3  14.6 
(1)  96  51  67  52 
H2L2  5  2.4  11  6.2 
(2) 100  100 100 100 
H2L3  0  0  12  4 
(3)  92  15  14  23 
H2L4  0  0  12  5 
(4)  96  0  17  16 
ZnCl2  0  1  5.6  0 
Gentamicin 100 100  99 100 
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3.6.1. Morphological changes of  S. aureus cells after treatment with complexes (1) and  
(2) 
To directly observe the morphological changes of the internal structure of 
bacterial cells after the treatment with complexes (1) and (2), TEM was employed. 
Complexes (1) and (2) were chosen since complex (1) exerts strong inhibition and 
complex (2) approximately half that of complex (1). As shown in Figure 11, when S. 
aureus (LSA88) was treated with complex (1), the majority of the cells presented debris 
with small structures resembling cell wall parts; some cells suggested the condensation 
of DNA (indicated by a star), in agreement with the moderate inhibition promoted by 
this complex on S.aureus cells (see Figure 11B). Figure 11C reveals the formation of 
membrane-derived vesicles (MVs) (indicated by an arrow), which can be a kind of 
defense mechanism against the drug, as suggested by Lee and co-workers [38]. 
According to their study, membrane-derived vesicles (MVs) are produced by Gram-
positive bacteria and the subsequent delivery to host cells could be related to the 
virulence since many virulence-associated proteins were identified in the S. aureus 
MVs. This was the first report describing the importance of MVs as vehicle for delivery 
of bacterial effector molecules to host cells. Figure 11D reveals the presence of DNA 
condensation (indicated by a star) and inner walls with aberrant division planes 
(indicated by arrows) which could be related to the inhibition of wall protein synthesis 
which, in turn, is directly related to the cellular division process [39]. Figure 12A shows 
control cells of S. aureus with a well defined cell wall and DNA during cell division 
after 24 h of incubation with complex (2). As shown in Figure 12B, the treatment with 
complex (2) promotes disruption of the cell, with the presence of holes and the 
extrusion of the cytosolic material. Thus, it is possible to suggest that the high inhibitory 
activity of complex (2) may be associated with the inhibition of the cell division process 
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of S.aureus cells, as an effect of the reduced integrity of S. aureus cell wall after 
treatment with this complex. Due to the presence of groups which resemble amino acids 
in their structures, complex (2) may be working as a host defense peptide (HDPs), 
defined as important effector molecules of the innate immune system, providing 
effective barriers against a wide range of invading microorganisms [40]. HDPs interfere 
with the cell wall biosynthesis machinery and TEM data strongly suggest that they 
promote local injuries in the cell wall layer leading, as a result of osmotic pressure, to 
the formation of membrane protrusions with cytoplasmic content [39]. This proposal is 
in good agreement with transmission electron micrographs, which indicate that the 
treatment of S. aureus with complex (2) may lead to lysis after 24 h of incubation. 
 
4. Conclusions 
In this work we have described the synthesis and characterization of four zinc 
complexes containing N,O-ligands. Complexes (1), (2) and (3) were characterized by x-
ray diffraction studies, revealing the presence of mononuclear compounds in the solid 
state. Complexes (1-4) promoted cell death of human leukemia THP-1, U937 and Molt-
4 cells in vitro. Complex (4) exhibited the highest cytotoxic activity with an IC50 value 
of 75 ± 1 µmol L-1 against U937, promoting cell death by apoptosis (confirmed by the 
Annexin V assay). Morphological investigations using TEM analysis revealed an 
intense association between mitochondria and the endoplasmic reticulum, and the 
formation of membrane blebs, typical of apoptotic cells, thus indicating that complex 
(4) is promoting cell death by an apoptotic mechanism.  
With respect to antibacterial activity, complex (2) showed the highest inhibitory 
activity, reaching almost 100% of inhibition against the three strains under investigation 
at a concentration of 10-2 mol L-1. This result demonstrates that the zinc complexes with 
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pyridine and phenol ligands are promising lead compounds in the search for new 
antibacterial drugs. Morphological investigations by TEM indicated that the 
antibacterial activity of complex (2) may be associated with the inhibition of cell wall 
protein synthesis, which affects cell division.  
We are currently carring out additional investigations which aim to shed light 
into the details of the apoptotic mechanism, as well as to evaluate the activity of 
complex (4) in vivo since no modern chemotherapy includes zinc adjuvants, even 
though zinc serum levels are usually low in leukemic children. 
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Appendix A. Supplementary material 
CCDC 852518, 852519 and 852520 contains the supplementary crystallographic 
data for this paper (complexes (1), (2) and (3), respectively). These data can be obtained 
free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. Dose-response curves were obtained by MTT 
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assay and are presented as supplementary material (Figures S1, S2 and S3, respectively 
for THP-1, U937 and Molt-4 cells). 
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Figure Captions 
 
Scheme 1. Scheme illustrating the synthesis of the zinc complexes (1)-(4). 
 
Figure 1. 1H NMR spectra for zinc complexes: a) complex (1), b) complex (2), c) 
complex (3) and d) complex (4). Each complex was dissolved in DMSO. 
 
Figure 2.View of the ORTEP-3 projection for (1) and the corresponding residue labeling 
scheme. Ellipsoids are shown at the 40% probability level.  
 
Figure 3.View of the ORTEP-3 projection for (2) and the corresponding residue labeling 
scheme. Ellipsoids are shown at the 40% probability level. 
 
Figure 4.View of the ORTEP-3 projection for (3) and the corresponding residue labeling 
scheme. Ellipsoids are shown at the 40% probability level. 
 
Figure 5. Proposed structures for some signals detected in the ESI(+)-MS spectra for 
complexes (2) (left) and (4) (right). 
 
Figure 6. Apoptosis induced by complex (4) in U-937 cells. The percentage of apoptotic 
cells was measured in a flow cytometer after treatment with complex (4) for 24 h. the 
cells were pre-stained with Annexin/PI. (A) Control. (B) Cisplatin – 50 µmol L-1. (C) 
Complex (4) – 200 µmol L-1. (D) Complex (4) – 400 µmol L-1. Viable cells (Q3), 
primary apoptosis (Q4), secondary apoptosis (Q2) and necrosis (Q1). 
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Figure 7. Transmission electron micrograph of U937 cells after treatment with complex 
(4) at a concentration of 100 µmol L-1 after 6 h of incubation. N= nucleus, ER= 
endoplasmatic reticulum. 
 
Figure 8. Transmission electron micrograph of U937 cells after treatment with complex 
(4) at a concentration of 200 µmol L-1 after 12h of incubation. M= mitochondria, ER= 
endoplasmatic reticulum, B= blebs, NC= nuclear chromatin, V= vacuoles. 
 
Figure 9. Transmission electron micrograph of THP-1 cells after treatment with 
complex (4), at a concentration of 100 µmol L-1 after 6 h of incubation. M= 
mitochondria, ER= endoplasmatic reticulum, V= vacuoles. 
 
Figure 10. Transmission electron micrograph of THP-1 cells after treatment with 
complex (4) at a concentration of 200 µmol L-1 after 12h of incubation. V= vacuoles. 
 
Figure 11. TEM of S. aureus cells. (A): Control; (B, C and D): after treatment with 
complex (1). 
 
Figure 12. TEM of S. aureus cells. (A): Control; (B): after treatment with complex (2).  
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Highlights 
 
1-Structures for the complexes were determined by X-ray diffraction and NMR. 
2- Complex (4) shows the highest cytotoxic activity promoting cell death by apoptosis. 
3- Morphological analysis of leukemia cells by TEM confirms cell death by apoptosis. 
4- Complex (2) reaches almost100% of inhibition against three strains of S. aureus. 
5- Morphological investigation by TEM suggests effect on bacteria cell division. 
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Graphical Abstract (synopsis) 
Herein we present the spectroscopic and structural characterization of  four new 
zinc complexes and biological results concerning the cytotoxic activity on human 
leukemia cells lines (THP-1, U937 and Molt-4) and  antimicrobial activity  in vitro 
against four Gram-positive bacteria (ATCC10832, ATCC25923, COL) and one animal 
strain S. aureus LSA88 (SEC/SEF/TSST-1+).  
 
 
  
52 
 
 
 
Graphical Abstract (figure) 
 
  
 
 
S. 
aureus 
